Press Releases

Apr 19, 2022 6:21am EDT

Greenwich LifeSciences Presents Phase IIb Data, Published at AACR 2022, Further Supporting the Role of GP2 in Preventing Metastatic Breast Cancer

Mar 03, 2022 9:19am EST

Greenwich LifeSciences Provides Updates on Upcoming Phase III Clinical Trial, Patent Filings, & AACR Meeting

Feb 03, 2022 6:00am EST

Greenwich LifeSciences to Present at 2022 BIO CEO & Investor Conference

Feb 01, 2022 6:00am EST

Greenwich LifeSciences Provides Update on Upcoming Phase III Clinical Trial, FLAMINGO-01

Jan 24, 2022 6:00am EST

Greenwich LifeSciences to Implement Stock Repurchase Program for up to $10 Million & to Extend Lock-up of Insiders for an Additional 1 Year

Dec 15, 2021 6:00am EST

Greenwich LifeSciences CEO Participates in TD Ameritrade Interview to Discuss 2021 SABCS Poster

Dec 09, 2021 6:29am EST

Greenwich LifeSciences Announces Presentation of 5 Year Data for GP2 Phase IIb Clinical Trial, Revealing Potential For New T Cell Platform Technology

Dec 08, 2021 7:00am EST

Greenwich LifeSciences to Participate in Multiple Interviews and Conferences

Dec 07, 2021 6:34am EST

Greenwich LifeSciences Expands Role of Industry Expert Dr. F. Joseph Daugherty to Include Medical Monitor for its Upcoming Phase III Clinical Trial

Dec 06, 2021 7:15am EST

Greenwich LifeSciences Announces Commencement of the First Commercial Line Filling of GP2